With high R&D investment and multi-field layout, Kinsey uses technology to protect the future of children

Release time:

2021-09-15

A few days ago, Changchun High-tech Industry (Group) Co., Ltd. released the 2021 annual corporate report, reporting the company's operation and management, talent investment, environmental protection and social responsibility in the past year. As a subsidiary of Changchun High-tech, Jinsai Pharmaceutical has shown good results in its annual report. It not only continues to support the research and development process with super high investment, but also actively develops multi-field layouts and strives to contribute technology to the better life of Chinese children and the wider population. strength.

High R&D investment, leading enterprise development with technology

Technological innovation is the inexhaustible driving force for enterprises to move forward. As a national genetic engineering new drug incubation base, Jinsai Pharmaceutical has always focused on scientific research and innovation, leading the development of the enterprise with hard-core strength. Taking growth hormone as an example, from the launch of the first domestically produced recombinant human growth hormone powder in 1998, to the development of the first recombinant human growth hormone liquid in Asia in 2005, to the launch of the world's first long-acting recombinant human growth hormone in 2014. For more than ten years, Sai Pharmaceutical has overcome many technical difficulties, surpassed many multinational companies, and demonstrated the innovative strength of Chinese companies. Therefore, it won the second prize of the National Science and Technology Progress Award.

At present, Jinsai Pharmaceutical R&D Center in Zhangjiang, Shanghai has completed the first two phases of three phases, and the new R&D center will also start construction and put into use one after another. Jinsai Pharmaceutical now has a complete core technology platform such as innovative drug design, drug screening platform, drug evaluation platform, process development and preparation platform, and has 775 R&D personnel, accounting for 13.2% of the total number of employees. In addition, Jinsai Pharmaceutical and nearly 20 colleges and universities including Jilin University, Dalian University of Technology, Shenyang Pharmaceutical Science and Technology are establishing continuous and stable school-enterprise cooperation. Various forms of scientific research cooperation are also being carried out with Shanghai Jiaotong University, Shandong University, and the Center for Excellence in Brain Science and Intelligent Technology of the Chinese Academy of Sciences. This not only established a first-class talent supply chain with core competitiveness for the company, but also established a good platform for the company's technology development, achievement transformation, and resource sharing. In 2021, Kinsey's R&D investment will increase by 89% compared to the previous year. "In the future, we expect to continue to invest more than 15% of the company's annual revenue in research and development, and with the comprehensive construction of Shanghai Zhangjiang R&D Center, Kinsey's overall drug research and development will also make great progress." Kinsey Pharmaceuticals Dr. Jin Lei, chief scientist, introduced.

Multi-field layout, solid service to a wider audience

With socio-economic development, the spectrum of childhood diseases has undergone tremendous changes. As an important participant in the field of children's health, Kinsey Pharmaceuticals is actively responding to the national strategic requirements in the face of new problems and challenges raised in the field of children's health, and starting from the pain points in the field of pediatrics to help children develop comprehensively and healthily.

In addition to continuing to co-create with experts in the field and top universities to promote the transformation of scientific research results; build a new technology platform to solve the problem of "stuck neck" diagnosis and treatment in pediatrics; use artificial intelligence detection and diagnosis tools to empower grassroots pediatric diagnosis and treatment; join hands with field experts to build China Children's standards, to fill the gaps at home and abroad. Jinsai Pharmaceutical is focusing on the core business of pediatrics, and has a comprehensive layout in pediatric fields including height management, sexual development, immunization, neonatal, child care, and child neuropsychiatry. It provides a complete diagnosis and treatment ecosystem such as investigation, device intervention and digital means, so that patients can get one-stop comprehensive services from diagnosis to intervention to follow-up. Dr. Jin Lei said: "In the next 20 years, we will redouble the efforts that Kinsey has made in the fields of growth hormone and pediatric endocrinology for the whole pediatric health management." While serving the field of children's growth retardation, Kinsey The pharmaceutical industry will continue to pay attention to various aspects such as childhood sexual developmental abnormalities, childhood overweight and obesity, childhood kidney and immune diseases, childhood neurological and language abnormalities, birth defects, and postural abnormalities.

In addition, Jinsai Pharmaceutical will also actively combine the development of new technologies to expand the fields of assisted reproduction, female endocrinology, anti-aging and tumors, and continuously meet the needs of a wider group of people for products and services. As of now, the first phase of the plan to acquire 51% of Chunan Biotech in three phases has been completed. After the completion of the plan, Jinsai Pharmaceutical will make full use of the existing molecular coupling technology platform of Chunan Bio to develop new products in line with strategic development, so that the company can quickly enter the field of elderly bone and joint diseases and dermatology. Three months ago, Kinsey Pharmaceuticals signed an agreement to acquire 68% equity of Hangzhou Wowei Medical, in order to seek new breakthroughs in the field of medical devices such as neonatal EEG measurement systems and non-invasive multi-parameter near-infrared tissue oxygen monitors.

Reference data:

Changchun Hi-Tech 2021 Annual Report

Chinanews.com: "Changchun High-tech: R & D investment of 1 billion, the three major indicators hit new highs last year"

Securities Times: "Changchun High-tech Revenue Breaks 10 Billion Jinsai Pharmaceutical's Multi-Product Line Layout Growth Can Be Expected"